Jul 29, 2020 1:00am EDT FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19: Currently in development by NeuroRx and Relief Therapeutics under Fast Track Designation
Jul 16, 2020 1:00am EDT NeuroRx and Relief Therapeutics Announce Data Monitoring Committee Determination to Continue Phase 2/3 Trial of RLF-100 for Critical COVID-19
Jun 24, 2020 1:30am EDT NeuroRx and Relief Therapeutics Announce Fast Track Designation Granted by the FDA to RLF-100 (Aviptadil) for the Treatment of Respiratory Distress in COVID-19
Jun 11, 2020 1:00am EDT Relief Therapeutics and NeuroRx Expand Clinical Trial Evaluating RLF-100 in Critically Ill COVID-19 Patients with Respiratory Failure to Houston Methodist Hospital
Jun 08, 2020 1:00am EDT Relief Therapeutics and NeuroRx Expand Clinical Trial of RLF-100 to All Patients with Critical COVID-19 and Respiratory Failure
Jun 01, 2020 4:03pm EDT Relief Therapeutics and NeuroRx Announce Enrollment of First Patients with RLF-100 in Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress
May 14, 2020 1:00am EDT Relief Therapeutics and NeuroRx Announce Final Manufacturing Validation of RLF-100 for Phase 2b/3 Clinical Trial in Patients with COVID-19 Associated Acute Respiratory Distress Syndrome
Mar 26, 2020 6:45am EDT RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
Mar 25, 2020 2:45pm EDT NeuroRx to discuss investigational drug for COVID-19 related Acute Respiratory Distress at Solebury Trout Virtual Global Healthcare Conference on March 26, 2020
Feb 10, 2020 8:13am EST NeuroRx: Phase 3 Drug for Suicidal Bipolar Depression to Present at BIO CEO Conference
